CTLA-4 inhibits T-cell proliferation and enhances Treg activity, while PD-1, expressed on multiple immune cells, suppresses antigen-specific T-cell responses upon binding PD-L1, which is upregulated in tumor and stromal cells and correlates with poor prognosis [12,69,74,75,76]. Here, CTLA4 is linked to neoplasm.